Sequential designs for ordinal phase I clinical trials

Biometrical Journal

Volumn 51, Issue 2, 2009, Pages 335-347

  Liu, Guohui ^a   Rosenberger, William F ^b   Haines, Linda M ^c  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b Krasnow Institute for Advanced Study   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Maximum likelihood estimator; Optimal designs; Proportional odds model

Indexed keywords

REGRESSION ANALYSIS;

CLINICAL TRIAL; ETHICAL CONSIDERATIONS; LIMITED DATA; MAXIMUM LIKELIHOOD ESTIMATOR; MAXIMUM-LIKELIHOOD ESTIMATE; OPTIMAL APPROACHES; OPTIMAL DESIGN; PHASE I; PROPORTIONAL ODDS MODEL; SEQUENTIAL DESIGN;

MAXIMUM LIKELIHOOD ESTIMATION;

ARTICLE; COMPUTER SIMULATION; PHASE 1 CLINICAL TRIAL; STATISTICAL MODEL; STATISTICS;

CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; MODELS, STATISTICAL;

EID: 66349102328     PISSN: 03233847     EISSN: 15214036     Source Type: Journal    
DOI: 10.1002/bimj.200800192     Document Type: Article

References (17)

1. Babb, J., Rogatko, A. and Zacks, S. (1998). Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine 17, 1103-1120.
2. Dragalin, V. and Fedorov, V. (2006). Adaptive designs for dose-finding based on efficacy-toxicity response. Journal of Statistical Planning and Inference 136, 1800-1823.
3. Gelmon, K. A., Latreille, J., Tolcher, A., Genier, L., Fisher, B., Forand, D., D'Aloisio, S., Vernillet, L., Daigneault, L., Lebecq, A., Besenval, M., Eisenhauer, E. (2000). Phase I dose-finding study of a new Taxane, RPR 109881A, administered as a one-hour intravenous infusion Days 1 and 8 to patients with advanced solid tumors. Journal of Clinical Oncology 18, 4098-4108.
4. Haberman, S. J. (1980). Discussion of McCullagh. Journal of the Royal Statistical Society, B 42, 136-137.
5. Haines, L. M., Perevozskaya, I. and Rosenberger, W. F. (2003). Bayesian optimal designs for phase I clinical trials. Biometrics 59, 591-600.
6. Kiefer, J. and Wolfowitz, J. (1960). The equivalence of two extremum problems. Canadian Journal of Mathematics 12, 363-366.
7. Liu, G. (2006). Sequential Designs for Logistic Phase I Clinical Trials. Doctoral dissertation, University of Maryland Graduate School, Baltimore, MD.
8. Liu, G., Rosenberger, W. F. and Haines, L. M. (2006). Sequential designs for logistic phase I clinical trials. Journal of Biopharmaceutical Statistics 16, 605-621.
9. Paul, R. K., Rosenberger, W. F. and Flournoy, N. (2004). Quantile estimation following non-parametric phase I clinical trials with ordinal response. Statistics in Medicine 23, 2243-2495.
10. Perevozskaya, I. (2001). Constrained Bayesian optimal designs for Phase I clinical trials. Doctoral dissertation, University of Maryland Graduate School, Baltimore, MD.
11. Perevozskaya, I., Rosenberger, W. F. and Haines, L. M. (2003). Optimal design for the proportional odds model. Canadian Journal of Statistics 31, 1-11.
12. Robertson, F., Wright, F. T. and Dykstra, R. L. (1988). Ordered Restricted Statistical Inference. Wiley, New York.
13. Silvapulle, M. J. and Burridge, J. (1986). Existence of maximum likelihood estimates in regression models for grouped and ungrouped data. Journal of the Royal Statistical Society, B 48, 100-106.
14. Simon, R., Freidlin, B., Arbuck, S. G., Collins, J. and Christian, M. C. (1997). Accelerated titration designs for phase I clinical trials in oncology. Journal of the National Cancer Institute 89, 1138-1147.
15. Tantiyaswasdikul, C. and Woodroofe, M. B. (1994). Isotonic smoothing splines under sequential designs. Journal of Statistical Planning and Inference 38, 75-88.
16. Whitehead, J. and Williamson, D. (1998). An evaluation of Bayesian decision procedures for dose-finding studies. Journal of Biopharmaceutical Statistics 8, 445-467.
17. Wu, C. F. J. (1985). Efficient sequential designs with binary data. Journal of the American Statistical Association 85, 156-162.